Page 1

EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2021 Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG , Md . , July 29 , 2021 - Emergent BioSolutions Inc. ( NYSE : EBS ) today reported financial results for the second quarter ended June 30 , 2021 . ● " Our second quarter performance demonstrates the strength of our strategy and diversified business model , " said Robert G. Kramer , president and chief executive officer of Emergent BioSolutions . " Through continued investment and innovation , we will play an important role in helping deliver solutions to the public health threats we face . We are proud to be resuming production of COVID - 19 vaccine batches following additional reviews and collaboration with the Food and Drug Administration and our manufacturing partner . " Kramer added , “ I am thankful for the relentless determination of our Emergent team across the globe to deliver for our patients , customers and partners . " FINANCIAL HIGHLIGHTS ( 1 ) ( $ in millions , except per share amounts ) Total revenues Net income Net income per diluted share Adjusted net income ( 2 ) Adjusted net income ( 2 ) per diluted share Adjusted EBITDA ( 2 ) ( $ in millions , except per share amounts ) Total revenues Net income Net income per diluted share Adjusted net income ( 2 ) Adjusted net income ( 2 ) per diluted share Adjusted EBITDA ( 2 ) emergent biosolutions® Q2 2021 $ 397.5 $ 4.6 $ 0.09 $ 18.0 $ 0.33 $ 49.5 YTD 2021 $ 740.5 $ 74.3 $ 1.37 $ 101.6 $ 1.87 $ 173.0 Q2 2020 $ 394.7 $ 92.7 $ 1.73 $ 105.7 $ 1.98 $ 156.1 YTD 2020 $ 587.2 $ 80.2 $ 1.51 $ 106.0 $ 1.99 $ 171.4 % Change 1 % ( 95 ) % ( 95 ) % ( 83 ) % ( 83 ) % ( 68 ) % 1 of 13 % Change 26 % ( 7 ) % ( 9 ) % ( 4 ) % ( 6 ) % 1 % Q2 2021 AND OTHER RECENT BUSINESS ACCOMPLISHMENTS Announced that the U.S. Food and Drug Administration ( FDA ) has informed the Company that it can resume production of Johnson & Johnson's COVID - 19 vaccine bulk drug substance at the Company's Bayview manufacturing facility . Supporting the U.S. government's smallpox preparedness efforts under contract options exercised by the Department of Health and Human Services ( HHS ) valued at approximately $ 182 million and $ 56 million to deliver ACAM2000® ( Smallpox ( Vaccinia ) Vaccine , Live ) and VIGIV [ Vaccinia Immune Globulin Intravenous ( Human ) ] ( VIGIV ) , respectively . Supporting the Canadian government's anthrax preparedness efforts under a new contract with the Public Health Agency Canada ( PHAC ) to deliver Anthrasil ( Anthrax Immune Globulin Intravenous [ human ] ) through March 2023 . Received approval from the Federal Agency for Medicines and Health Products ( FAMHP ) of Belgium for Trobigard® Auto - injector ( atropine sulfate 2mg / obidoxime chloride 220mg ; solution for injection ) , an